Regulus Therapeutics Inc. (RGLS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Regulus Therapeutics Inc. (RGLS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.28

0.05 (4.49%)

At close: Jan 15, 2025, 2:44 PM

undefined% (undefined)

Bid	1.27
Market Cap	83.66M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.02
PE Ratio (ttm)	-1.25
Forward PE	n/a
Analyst	Buy

Ask	1.28
Volume	227,836
Avg. Volume (20D)	355,409
Open	1.24
Previous Close	1.23
Day's Range	1.20 - 1.28
52-Week Range	1.08 - 3.79
Beta	undefined

About RGLS

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 9, 2012

Employees 32

Stock Exchange NASDAQ

Ticker Symbol RGLS

Website https://www.regulusrx.com

Analyst Forecast

According to 6 analyst ratings, the average rating for RGLS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 448.03% from the latest price.

Buy 83.33%

Hold 16.67%

Sell 0.00%

Stock Forecasts

Why Price Moved

6 months ago · Source

-18.33%

Regulus Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

10 months ago · Source

+2.97%

Regulus Therapeutics shares are trading higher after Wells Fargo maintained an Equal-Weight rating on the stock and raised its price target from $2 to $3.

News

8 months ago · investorplace.com

The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028

Finding good investment opportunities in the constantly changing stock market is similar to uncovering hidden treasures. Certain cheap stocks to buy are particularly noteworthy because they can yield ...

9 months ago · seekingalpha.com

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD

Regulus Therapeutics Inc. achieved positive results in cohort 2 of phase 1b study, using RGLS8429 for patients with autosomal polycystic kidney disease; Improvement of PC1 & PC2 proteins and reduction...

10 months ago · zacks.com

Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study

Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.

1 year ago · gurufocus.com

Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance

Long-established in the Biotechnology industry, Regulus Therapeutics Inc ( RGLS , Financial) has enjoyed a stellar reputation. It has recently witnessed a surge of 13.27%, juxtaposed with a three-mont...

1 year ago · zacks.com

Regulus (RGLS) Surges on Enrollment Completion for RGLS8429

Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.

2 years ago · seekingalpha.com

Regulus Therapeutics, Inc. (RGLS) Q3 2022 Earnings Call Transcript

Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Jay Hagan - President, CEO & Director Denis Drygin -...

2 years ago · zacks.com

Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study

Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.

2 years ago · pennystocks.com

Hot Penny Stocks to Know About Right Now? 3 to Watch

Here's what you need to know about trading penny stocks on September 13th The post Hot Penny Stocks to Know About Right Now? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Informat...

2 years ago · seekingalpha.com

Regulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q2 2022 Results - Earnings Call Transcript

Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Joseph Hagan - President & CEO Conference Call Partici...

2 years ago · pennystocks.com

Top Penny Stocks to Buy Now? 3 to Watch in June 2022

Can these penny stocks make gains next month? The post Top Penny Stocks to Buy Now?

2 years ago · pennystocks.com

Check These 3 Penny Stocks Out For Your Watchlist

Are these penny stocks on your watchlist right now? The post Check These 3 Penny Stocks Out For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

2 years ago · investorplace.com

7 Penny Stocks With 10x Potential This Year

These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward.

2 years ago · pennystocks.com

How to Trade Penny Stocks When the Stock Market Crashes

Here are three tips for trading penny stocks during a bear market The post How to Trade Penny Stocks When the Stock Market Crashes appeared first on Penny Stocks to Buy, Picks, News and Information | ...

2 years ago · seekingalpha.com

Regulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q1 2022 Results - Earnings Call Transcript

Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Joseph Hagan - President, CEO & Director Conference Call ...

2 years ago · zacks.com

Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug

The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022.

2 years ago · pennystocks.com

Top Penny Stocks to Watch as AFI Stock Shoots Up By Over 230%

Why these penny stocks climbed during trading today The post Top Penny Stocks to Watch as AFI Stock Shoots Up By Over 230% appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...